Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study
ConclusionThe study demonstrated high adherence to sc IFN β-1a treatment with an added benefit of PSP participation. More than half of the patients remained relapse-free over a 24-month period. No new safety concerns to sc IFN β-1a treatment were observed.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT02921035, NCT02921035. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - November 28, 2023 Category: Neurology Source Type: research
Clinical trials of inhaled interferon beta-1a (SNG001) in COVID-19 patients in the home and hospital
Conclusions: SNG001 was well tolerated across trials and should continue to be investigated for COVID-19 in the home and hospital settings. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Monk, P. D., Brookes, J., Tear, V., Batten, T., Mankowski, M., Gabbay, F., Davies, D., Brightling, C., Kraft, M., Djukanovic, R., Holgate, S., Wilkinson, T. Tags: Respiratory infections and bronchiectasis Source Type: research
Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
Expert Rev Clin Immunol. 2023 Sep 11:1-17. doi: 10.1080/1744666X.2023.2248391. Online ahead of print.ABSTRACTINTRODUCTION: Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.AREAS COVERED: Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the ref...
Source: Expert Review of Clinical Immunology - September 11, 2023 Category: Allergy & Immunology Authors: Uwe Klaus Zettl Paulus Stefan Rommer Orhan Aktas Torsten Wagner Joachim Richter Patrick Oschmann Lukas Cepek Birte Elias-Hamp Klaus Gehring Andrew Chan Michael Hecker Source Type: research
Evolution of the RebiSmart ® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - August 9, 2023 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years
. (Source: Expert Opinion on Drug Delivery)
Source: Expert Opinion on Drug Delivery - June 8, 2023 Category: Drugs & Pharmacology Authors: Francesco Piras Lilian Arnaud Eric Henninger Matthew Keiser Andrea Seitzinger Dominic Jack Quentin Le Masne Source Type: research
Alemtuzumab for multiple sclerosis
CONCLUSIONS: Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with at least one adverse event for people with relapsing-remitting MS at 36 months. The certainty of the evidence for these results was very low to low.PMID:37272540 | PMC:PMC10240561 | DOI:10.1002/14651858.CD011203.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - June 5, 2023 Category: General Medicine Authors: Rachel Riera Maria Regina Torloni Ana Luiza C Martimbianco Rafael L Pacheco Source Type: research
HTA80 Cost-Effectiveness of Ocrelizumab Compared with Dmt for the Treatment of Relapsing-Remitting Multiple Sclerosis in Czech Republic
Ocrelizumab represents a generally well-tolerated, high-efficacy disease-modifying therapy (DMT) approved in Czech Republic for the RRMS. The aim of this study was to evaluate the cost-effectiveness of ocrelizumab compared with other DMT (glatiramer acetate, interferon beta-1a, interferon beta-1b, teriflunomide) for the treatment of RRMS from payer perspective. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M. Pour, Nov ák J, S. Motylova, D. Skalicky, K. Krihova, J. Dolezel Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing –Remitting Multiple Sclerosis in the United States
ConclusionTreatment with ozanimod was associated with substantial reductions in annual drug costs and total MS-related healthcare costs to avoid relapses compared with other DMTs. In the fixed-budget analysis, ozanimod demonstrated a favorable cost-effective profile relative to other DMTs. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 18, 2023 Category: Neurology Source Type: research
